Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | CTSA | P10619 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678819 | 1.00 | GSK3B (0.43) | GSK3BCTSAHPGDSAPLNRCYP1A2 | |
| SCHEMBL8237566 | 0.84 | CYP1A2 (0.44) | CTSAAPLNRCYP1A2POLBTDP1 | |
| SCHEMBL9648449 | 0.83 | CTSA (0.43) | GSK3BCTSAAPLNRCYP1A2POLB | |
| SCHEMBL3403968 | 0.81 | CTSA (0.45) | CTSAAPLNRCYP1A2POLBTDP1 | |
| SCHEMBL28712036 | 0.81 | KDM4E (0.52) | GSK3BCYP1A2PTPN1POLBTDP1 | |
| SCHEMBL24443478 | 0.80 | CTSA (0.44) | CTSAAPLNRCYP1A2KDM4EMEN1 | |
| SCHEMBL29689811 | 0.80 | CTSA (0.44) | CTSAAPLNRCYP1A2KDM4EMEN1 | |
| SCHEMBL8866132 | 0.80 | CTSA (0.45) | CTSAAPLNRCYP1A2POLBTDP1 | |
| SCHEMBL2305425 | 0.79 | MAPT (0.55) | CYP1A2KDM4EGAAKMT2A | |
| Hydrochloric Acid SCHEMBL20524548 | 0.79 | CTSA (0.43) | CTSAAPLNRCYP1A2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110772-A1 | IMIDAZOLO-PYRIDINE DERIVATIVES AND USES THEREOF | 엘젠테라퓨틱스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| EP-4514802-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023208986-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-11-02 | — | — | WO | disclosed |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| CN-112351983-A | Substituted propionamides as inhibitors of nucleases | 马萨里克大学 | 2021-02-09 | — | — | CN | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | GSK3B 3616/4885CTSA 415/4885HPGDS 3911/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | GSK3B 3616/4885CTSA 415/4885HPGDS 3911/4885 |
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | GSK3B 3336/4885CTSA 3038/4885HPGDS 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.